StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Get Rating) in a report issued on Thursday. The firm issued a sell rating on the medical research company’s stock.
OpGen Price Performance
NASDAQ:OPGN opened at $1.47 on Thursday. OpGen has a 12-month low of $0.93 and a 12-month high of $17.90. The firm has a market capitalization of $3.94 million, a price-to-earnings ratio of -0.08 and a beta of -0.22. The stock’s 50 day moving average price is $1.61 and its two-hundred day moving average price is $0.75. The company has a quick ratio of 1.05, a current ratio of 1.11 and a debt-to-equity ratio of 0.29.
Institutional Investors Weigh In On OpGen
Hedge funds have recently added to or reduced their stakes in the business. HRT Financial LP acquired a new position in shares of OpGen in the fourth quarter valued at $26,000. FNY Investment Advisers LLC bought a new stake in shares of OpGen during the 4th quarter worth about $232,000. Vanguard Group Inc. raised its holdings in OpGen by 39.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock valued at $537,000 after acquiring an additional 534,960 shares during the period. Citadel Advisors LLC lifted its position in OpGen by 571.0% during the third quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock worth $29,000 after acquiring an additional 85,754 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of OpGen during the third quarter worth approximately $1,517,000. Institutional investors and hedge funds own 16.36% of the company’s stock.
OpGen Company Profile
OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm’s also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms.
- Get a free copy of the StockNews.com research report on OpGen (OPGN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.